Prostate Cancer

Two true sentences: prostate cancer kills more American men than any cancer except lung cancer, and most men diagnosed with it will die of something else entirely. The disease spans that whole spectrum, which is why the diagnosis alone tells you very little. Some prostate cancers are so slow they will never matter in a man's lifetime and deserve monitoring rather than treatment. Others are aggressive and demand action. The grade and stage separate those worlds, and the first job after diagnosis is knowing which world you are in. Worldwide it is the most common cancer in men in more than a hundred countries and ranks fifth in cancer deaths. Take it seriously, and then find out exactly how seriously yours needs to be taken.

For the right cancer, yes, and it is now the recommended path for most low-risk disease. Active surveillance is not neglect: it is scheduled PSA checks, MRI and periodic biopsies, with treatment triggered the moment the cancer declares different intentions. Most men on surveillance for low-risk disease never need treatment, and they keep their continence and sexual function in the meantime. The hard part is psychological, living with a monitored cancer. For many men that trade, function kept against vigilance required, is the best deal in oncology.

Not necessarily, but this deserves numbers instead of reassurance. After prostate removal, roughly half of men have lasting trouble with erections, even in experienced hands. Nerve-sparing technique, penile rehabilitation and time all improve the odds, but the pills do not work for everyone afterward. When they fail, injections succeed for most men, and a penile implant is the definitive answer for the rest. Radiation is gentler on erections up front, but the decline arrives gradually over the following years, and a few years out the numbers sit closer to surgery than most men expect. Ejaculation changes permanently after prostate removal, which the conversation should cover beforehand. Your function going in matters, and so does asking about function before you choose a treatment rather than after. These questions are not vanity. They are quality of life.

Your risk group writes the menu, and your age and priorities pick from it. For very low and low risk disease, active surveillance is the standard recommendation, not the consolation prize: monitoring with PSA, MRI and periodic biopsy, with curative treatment held in reserve for the minority who need it. For favorable intermediate risk, surveillance and treatment are both legitimate, and the choice leans on the details: how much pattern 4 is present, how many cores are involved, and what matters most to you. When that call is close, a genomic test run on the biopsy tissue can help tip it. Unfavorable intermediate risk usually means treatment. Surgery and radiation cure localized disease at similar rates, so the real choice is between side effect profiles. Surgery front loads its costs, the recovery, the leakage risk and the erection risk, and then improves from there. Radiation is easier up front and collects gradually, from the bowel, the bladder and, over the years, the erections. High risk disease gets treated with intent, often radiation combined with hormonal therapy, or surgery with the understanding that radiation may follow.

Age threads through all of it. A man in his fifties is choosing for three or more decades, which argues for durability. A man in his eighties with a slow cancer may never need anything but watching. Whatever your group, ask each specialist for their own numbers, because surgeons lean surgery, radiation oncologists lean radiation, and both can be right. This is a decision you can only make once. With prostate cancer, you usually have the time to make it right for you.

A biopsy today can tell you far more than a Gleason score. Genomic tests run on the cancer tissue itself read the tumor's biology and estimate how it is likely to behave. Decipher is the most widely validated and helps predict the risk of spread. Prolaris, from Myriad, scores how fast the cancer cells are dividing. Oncotype GPS reads a panel of genes aimed at the surveillance decision. Artera is a newer test that uses artificial intelligence on the pathology slides themselves. What these change is real decisions: whether a favorable intermediate cancer can be watched, how long hormone therapy should ride along with radiation, and how aggressive the overall plan needs to be.

Separate from all of these is germline genetic testing, a blood or saliva test of the genes you were born with, BRCA among them. It is recommended for men with high risk or metastatic disease and matters to your relatives as well as to you, because it can change both your treatment and their screening. None of these tests decides for you. They shrink the guesswork.